Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
NCT ID: NCT06339138
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
589 participants
OBSERVATIONAL
2018-06-27
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. In tissue, to discover and validate DNA methylation markers (MDMs) for detection of malignant renal and urothelial tumors.
II. In blood, to assess the accuracy of candidate MDMs from above for detection of malignant renal and urothelial tumors.
OUTLINE: This is an observational study.
Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational
Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
Non-Interventional Study
Non-interventional study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Interventional Study
Non-interventional study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma
* Age \>= 18 years
* CASE BLOODS AND URINE:
* Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma
* Age \>= 18 years
* HEALTHY CONTROL BLOODS AND URINE:
* Patients has undergone negative hematuria workups (defined as negative abdominal imaging and negative cystoscopy
* Age \>= 18 years
Exclusion Criteria
* Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD)
* The current target pathology is a recurrence
* Patient has undergone any prior radiation therapy to target lesion prior to surgery
* Patient has received chemotherapy class drugs in the 5 years prior to surgery
* Patient has had any transplants prior to surgery
* Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X
* Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease
* RENAL CONTROL TISSUE:
* Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD).
* Patient has inflammation, atypia, or hyperplasia of the parenchyma
* Patient has a current or past history of renal cancer.
* Patient has undergone any prior radiation therapy to target lesion prior to surgery
* Patient has received chemotherapy class drugs in the 5 years prior to surgery
* Patient has had any transplants prior to surgery
* Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X
* Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease
* UROTHELIAL CONTROL TISSUE:
* Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD)
* Patient has inflammation, atypia, or hyperplasia of the urothelium
* Patient has a current or past history of urothelial cancer
* Patient has undergone any prior radiation therapy to target lesion prior to surgery
* Patient has received chemotherapy class drugs in the 5 years prior to surgery
* Patient has had any transplants prior to surgery
* Patient has confirmed or presumed lynch
* CASE BLOODS AND URINE:
* Patient has known primary cancer outside of the kidney within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers)
* Patient has had surgery to completely or partially remove current target pathology
* Patient has undergone any prior radiation therapy to target lesion prior to plasma and urine collection
* Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection
* Patient has had any transplants prior to plasma and urine collection
* Patient has confirmed or presumed lynch
* Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD)
* HEALTHY CONTROL BLOODS AND URINE:
* Patient has known primary cancer outside of the urothelium within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers)
* Current target pathology is a recurrence
* Patient has undergone prior radiation therapy in the 5 years prior to plasma and urine collection
* Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection
* Patient has had any transplants prior to plasma and urine collection
* Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD)
* Patient has confirmed or presumed lynch
* Gross urinary incontinence
* Patient has undergone cystectomy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John B. Kisiel, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic in Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-00971
Identifier Type: REGISTRY
Identifier Source: secondary_id
17-010944
Identifier Type: OTHER
Identifier Source: secondary_id
17-010944
Identifier Type: -
Identifier Source: org_study_id